Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.37 |
| ▸ | ARG2 | P78540 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3362202 | 0.89 | ARG1 (0.38) | L3MBTL1ARG1ARG2SMN1; SMN2 | |
| SCHEMBL31093131 | 0.84 | GAA (0.34) | L3MBTL1ARG1ARG2MAPTPOLB | |
| SCHEMBL6454219 | 0.82 | L3MBTL1 (0.61) | L3MBTL1MAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL6913115 | 0.81 | L3MBTL1 (0.64) | L3MBTL1MAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL31093032 | 0.80 | KDM1A (0.33) | ARG1ARG2MAPTPOLBALDH1A1 | |
| SCHEMBL2911096 | 0.80 | L3MBTL1 (0.63) | L3MBTL1ARG1ARG2MAPTPOLB | |
| SCHEMBL886919 | 0.78 | GLA (0.56) | MAPTALDH1A1SMN1; SMN2GLAKDM4E | |
| SCHEMBL2793942 | 0.78 | L3MBTL1 (0.41) | L3MBTL1MAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL31093000 | 0.78 | — | — | |
| SCHEMBL29973401 | 0.75 | L3MBTL1 (0.50) | L3MBTL1ARG1ARG2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | L3MBTL1 1046/4885ARG1 3672/4885ARG2 3814/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | L3MBTL1 812/4885ARG1 2817/4885ARG2 2048/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | L3MBTL1 987/4885ARG1 1999/4885ARG2 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.